> Genzyme is sponsoring a gene therapy trial to determine how its experimental drug works against peripheral arterial disease. Report
> YM BioSciences' partner, Oncoscience, has commenced patient treatment for its Phase III trial of nimotuzumab in combination with radiation in children with diffuse, intrinsic pontine (brain stem) glioma. Release
> Vertex has modified its Phase II study of VX-950, adding two new patient pools to address specific questions about the drug's activity. Report
> As a follow-up to last month's Chapter 11 filing, SeraCare is consolidating its operations in Milford, MA. Report
> A.P. Pharma has received the green light to start a Phase III trial of APF530 for chemotherapy-induced nausea and vomiting. Release
> British scientists are investigating a protein-blocking drug that may reduce the damage caused by a heart attack. Report
> An experimental vaccine has demonstrated efficacy against the Marburg virus in animals infected with the disease. Article
And Finally... Pfizer CEO and Chairman Hank McKinnell will face new scrutiny of his $83 million retirement package at today's annual shareholders meeting. He gets the gold while shareholders watched stock prices slide 43 percent over the last five years. Article